Contained herein is an opinion of CLZR......
Wednesday October 11, 6:00 am Eastern Time
Press Release
The Wall Street Transcript Publishes Anti-Aging & Longevity Investing Issue
INTERNET WIRE -- Three leading analysts and top management from eleven sector firms examine the outlook for Anti-Aging & Longevity Investing in this special 56-page issue from The Wall Street Transcript. (212/952-7433) or www.twst.com/info/info187.htm
In a vital review of this sector for investors and industry professionals, this valuable 56-page Special Issue features:
1) Anti-Aging & Longevity Investing - In an-depth (10,800 words) Analyst Interview, Lorne Caplan, Managing Director, Caroline Goodman, Research Analyst, and Scott Baily, Vice President, all at BlueStone Capital Partners, examine the outlook for the sector, demographic-based investing, anti-aging medicine target, and share specific stock recommendations.
Goodman reports on Sangamo BioSciences (Nasdaq:SGMO - news). "Their technology looks at transcription factors. They engineer transcription factors, which are proteins that actually bind the DNA and are able to turn them on and turn them off, or otherwise regulate them. They basically call this technology the Universal Gene Recognition because it can bind DNA from any organism. This obviously has a lot of commercial potential ranging from pharmaceutical drug discovery to human therapeutics, to clinical diagnostics."
According to Baily, "Coherent (Nasdaq:COHR - news) is the industry leader in all of the segments that they target. Coherent pioneered the development and use of lasers in ophthalmology in 1970. Since then the company has been a market leader, and today, the company addresses all three of the main market segments."
"In the dental sector, I follow BioLase Technology (Nasdaq:BLTI - news), which I think is currently the technological leader worldwide for hard tissue dental procedures because of its flagship product, Waterlase," states Baily. "The Waterlase system uses a revolutionary technology that combines both laser energy and a water spray, which is known as the HydroKinetic process. The Waterlase system basically works by having the laser energy transfer directly to water particles kinetic energy that accelerates the water, which causes it to burst into small pieces, thereby creating a powerful laser system that effectively targets and cuts hard tissue. What I think is so impressive about the BioLases's technology is that by using the Waterlase system, these dental procedures can be done painlessly and 98% of the time use no anesthesia. Obviously, we think the outlook for BioLase is quite promising."
Baily highlights Candela (Nasdaq:CLZR - news), "Candela is not only a technology and market leader in the hair removal market, but they are also a leader in the vascular market. This past March, Candela introduced a new product, the Vbeam, that addresses the vascular market, and they are having great success with it. The Vbeam treats the widest range of vascular lesions such as facial spider veins, scars, stretch marks, and port wine stains. The primary competitive advantages of the Vbeam is less pain and no redness (purpura) for patients, and a lower price point for the physician. It sells for about $79,500 versus the competition that can easily top $100,000."
Goodman focuses on Genzyme Transgenics (Nasdaq:GZTC - news). "An area that I have a lot of interest in is transgenic technology. The biggest player there, in this country at least, is Genzyme Transgenics. They will most likely be the first company out there with a transgenic animal-derived protein. This is a booming field because there are a lot of protein therapeutics that are coming down the pipeline and in many cases large-scale production of such proteins is only possible through transgenic animals."
Caplan reports on the blood substitutes and blood products area, "As you know there's a great deal of difficulty getting blood transfusions in many cases matching those blood types. Blood banks run short a great many times. So we're looking for synthetic blood types to use in surgical procedures as well as in trauma patients, and Biopure (Nasdaq:BPUR - news) has a variety of different products, one has actually been approved, and there are others in the pipeline."
2) CEO interviews (average 2,500 words). Top management of eleven sector firms examine the outlook for their firm and the sector. Firms include:
Ostex International, Weider Nutrition International, Akorn, Cholestech, HEARx, Medamicus, MotherNature.com, Natrol, PacificHealth Laboratories, PolyMedica, ZEVEX International.
To obtain a copy of this 56-page Anti-Aging & Longevity Investing issue, call (212) 952-7433 or see www.twst.com/info/info187.htm
The Wall Street Transcript is a premier weekly investment publication interviewing market professionals for serious investors for over 37 years.
The Wall Street Transcript has launched a new free service where investors can ask the above company (or any public company) a question at www.qawire.com
The Wall Street Transcript does not endorse the views of any interviewee nor does it make stock recommendations.
--------------------------------------------------------------------------------
Contact:
Peter McLaughlin
The Wall Street Transcript
212-952-7433 |
